​What medications does Selpercatinib interact with?

In 2020, Selpercatinib was approved by the FDA as the first highly selective RET inhibitor for the treatment of a variety of cancers caused by RET gene fusions and mutations. It effectively inhibits the proliferation of cancer cells by blocking RET kinase activity. The drug has demonstrated strong anti-cancer potential in a variety of RET-related cancer patients.

What medications does Selpercatinib interact with?

While using this medicine, it is important to be aware of drug interactions as some medications may affect their efficacy or increase side effects.

1. Strong and moderate CYP3A inducers

Combination with strong or moderate CYP3A inducers reduces plasma concentrations of Selpercatinib and may impair anti-tumor effects. Concomitant use of these inducers is recommended.

2. CYP2C8 and CYP3A substrates

Selpercatinib is a moderate inhibitor of CYP2C8 and a weak inhibitor of CYP3A. Combination with these substrate drugs increases plasma concentrations and may increase the risk of adverse effects. If unavoidable, use should be carried out in accordance with the recommendations of the relevant drug label.

What are the adverse effects of Selpercatinib?

When using Selpercatinib, there may be some adverse reactions, and understanding these reactions can help to manage them in a timely manner.

1. Hair loss

During the course of treatment, patients may experience significant hair thinning or loss. This type of hair loss is usually temporary and may have an impact on the patient's physical appearance and psychological state. Patients can choose to wear a wig or take other cosmetic measures to cope with this change.

2. Nail poisoning

During treatment, the nails may become discolored, brittle, or delaminated, which may affect daily life and the aesthetics of the nails. To alleviate these discomforts, patients can protect their nails with moisturizers and avoid exposure to harsh chemicals such as detergents and solvents to reduce damage to the nails.

What are the indications for Selpercatinib?

The following is a detailed description of the indications for Selpercatinib to help patients understand the scope of treatment of the drug.

1. RET fusion-positive thyroid cancer

Indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with an FDA-approved test-confirmed RET gene fusion, requiring systemic therapy, and not responding to radioactive iodine therapy.

2. Medullary/lymphoma with FGFR1 rearrangement

Selpercatinib is indicated for the treatment of adult patients with relapsed or refractory myeloid/lymphoid tumors (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangements.

[Warm tips] Maintaining a positive mindset can help with treatment, and seeking support from family, friends or professionals when facing challenges. A good state of mind can help you cope with the changes that come with treatment.